Results 221 to 230 of about 347,205 (251)

Development of an 8-valent <i>Salmonella</i> and <i>Shigella</i> MAPS vaccine. [PDF]

Front Immunol
Boerth EM, Roffler B, Hancock Z, Gong J, MacLennan CA, Zhang F, Lu YJ.   +6 more
europepmc   +1 more source

Purification of Advanced Therapeutics by Flow‐Through Pseudo‐Affinity Chromatography: Bi‐Specific mABs, Fc Fusion Proteins, and Adeno‐Associated Viruses

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Modern biopharmaceutical manufacturing requires purification platforms capable of processing structurally and functionally diverse products while addressing the challenge of removing persistent and high‐risk host cell proteins (HCPs).
Wenning Chu, Eduardo Barbieri, Arianna Minzoni, Shriarjun Shastry, Jacob P. LeBarre, Qingbo Shu, Taufika Williams, Xuanwen Li, Divya Chandra, Xuankuo Xu, Jerome Bill, David Roush, Joseph Taris, Patrick Gilbert, Andre Kiesewetter, Oliver Rammo, Michael Schulte, Christopher Major, Trina Mouchahoir, Steven Cramer, Cristiana Boi, Ruben G. Carbonell, Abraham Lenhoff, Stefano Menegatti   +23 more
wiley   +1 more source

Estimated pneumococcal disease burden in children due to serotypes covered by different pneumococcal conjugate vaccines in five Latin American countries. [PDF]

Front Pediatr
Warren S, Bolanos R, Rey-Ares L, Reyes JM, Huerta JL, Ranzi A, Alexandre RF, Abalos MG, Huang L.   +8 more
europepmc   +1 more source

High Cell Density Cultivation of HEK293 Cells Using a 2L Membrane‐Stirred Bioreactor

Biotechnology and Bioengineering, EarlyView.
ABSTRACT The use of perfusion systems for the continuous cultivation of animal cells at high cell density (HCD) for the production of recombinant proteins, viruses, and viral vectors has many advantages. Besides an enhancement of volumetric productivity and high cell viability, the product quality can be improved through a steady‐state environment ...
Lennart Jacobtorweihe, Yasemin van Heuvel, Kathrina Scheiermann, Patrick Bongartz, Yvonne Genzel, Udo Reichl   +5 more
wiley   +1 more source

Indirect effect and pneumococcal conjugate vaccines

Педиатрическая фармакология, 2009
L. Temimi
doaj   +2 more sources

Analytical Characterization of Pneumococcal Vaccine Conjugates Using SEC-MALS Technique. [PDF]

Methods Protoc
Wright C, Chellappan G, Mydland A, Penumaka GJ, Karengil G, Seth H, Datta A, Kapre SV.   +7 more
europepmc   +1 more source

Provincial Trends in Childhood Vaccine Coverage in Afghanistan From 2000 to 2024: An Ecological Study of Findings From the Institute for Health Metrics and Evaluation. [PDF]

Cureus
Khan A, Tidman M.
europepmc   +1 more source

Anticipating impact of implementing PCV20 or PCV21 vaccines for older adults in the immunisation programme for invasive pneumococcal disease, using nationwide surveillance data, Israel, 2009 to 2024. [PDF]

Euro Surveill
Rieger R, Yahav D, Margalit I, Wieder-Finesod A, Azulay H, Ghanem-Zoubi N, Atamna A, Schindler Y, Abu Zayyad H, Dagan R, Regev-Yochay G, Israeli Adult Pneumococcal Invasive Disease (IAIPD) group.   +11 more
europepmc   +1 more source

Fluorinated carbohydrate-based vaccines. [PDF]

Chem Sci
Chikunova E, Suri J, Siebold K, Gilmour R.   +3 more
europepmc   +1 more source

Economic Evaluation of PCV21 Use in Populations with Increasing Serotype 4 Invasive Pneumococcal Disease in the US: An Attributable Fraction Threshold Analysis. [PDF]

Infect Dis Ther
Yi Z, Owusu-Edusei K, Flem E, Feemster K, Elbasha EH.   +4 more
europepmc   +1 more source